The advance is being hailed not just for amyloidosis patients but also as a proof-of-concept that CRISPR could be used to treat many other, much more common diseases. trib.al/UkhIkyE

Marianna Fontana Sarah Cuddy BWH Amyloidosis Program Indeed. This was on the next slide I do believe that imaging is a more reliable solution. We need to figure out how to re-characterize this "gold standard" reference. CR on its own can be FP and FN just for diagnostic purposes. Outcomes based approach will win in the end